Tag: clinical
OPM announces its 2023 annual results and provides an update on its clinical developments – 03/26/2024 at 6:00 p.m.
To receive information from ONCODESIGN PRECISION MEDICINE (OPM) in real time, send a request to [email protected] Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker: ALOPM), a biopharmaceutical company specializing in precision…
Inventiva announces positive results from the proof-of-concept Phase II clinical trial, LEGEND, combining lanifibranor and empagliflozin in patients with MASH/NASH and type 2 diabetes – 03/18/2024 at 9:00 p.m.
Daix (France), Long Island City (New York, United States), March 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
OSE Immunotherapeutics announces the end of recruitment in the Phase 2 clinical study of Lusvertikimab evaluated in patients suffering from ulcerative colitis – 03/18/2024 at 07:30
Nantes, France – March 18, 2024, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces the end of recruitment in the Phase 2b clinical trial evaluating the…
Nicox plans to secure funding to support the clinical development of NCX 470
By Arnaud Bivès Published on 03/13/2024 at 08:40 a.m. (Boursier.com) — Nicox whose resources are focused on…
Sensorion announces that the primary endpoint of the Phase 2a clinical study of SENS-401 in the preservation of residual hearing has been achieved – 03/11/2024 at 07:30
Sensorion announces that the primary endpoint of the Phase 2a clinical study of SENS-401 in the preservation of residual hearing has been achieved•The presence of SENS-401 is confirmed in the…
Bayer: clinical trials in AMD and DME
(CercleFinance.com) – The Lancet has published clinical trial data for aflibercept 8 mg (Eylea™ 8 mg) from the pivotal phase III PULSAR study in neovascular age-related macular degeneration (AMD) and…
Inventiva announces the resumption of screening in the Phase III clinical study, NATiV3, evaluating lanifibranor in NASH – 03/07/2024 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), March 7, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva: After a potential serious effect on a patient, Inventiva must pause its clinical trials
(BFM Bourse) – The stock price of the Burgundy biotechnology firm falls after bad news in the context of a clinical study concerning lanifibranor, its most advanced drug candidate against…
Inventiva publishes its preliminary financial information for the 2023 fiscal year¹ and provides an update on its NATiV3 clinical study – 02/15/2024 at 10:35 p.m.
Daix (France), Long Island City (New York, United States), February 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Biosenic raises 500,000 euros to finance an American clinical study
(AOF) – Biosenic announces that it has raised 500,000 euros in gross proceeds through a private placement of 12 million new shares at an issue price of 0.041 euros per…
Dassault Systèmes: The number of clinical trials slows down, sales of Dassault Systèmes software are slipping
(BFM Bourse) – The publisher of computer-aided design and manufacturing software delivered both results below expectations in the fourth quarter as well as disappointing forecasts. The poor performance of licenses…
Valbiotis: commercial and clinical roadmap for 2024
By Olivier Cheilan Published on 01/16/2024 at 6:05 p.m. Photo credit © Valbiotis (Boursier.com) — Valbiotis clarified its…